<DOC>
	<DOCNO>NCT00002237</DOCNO>
	<brief_summary>The purpose study determine high amount peldesine safe . This study also see amount peldesine effective lower HIV level blood .</brief_summary>
	<brief_title>A Study Peldesine ( BCX-34 ) HIV-Infected Patients</brief_title>
	<detailed_description>Patients give either BCX-35 placebo 14 28 day . Plasma viral load determine MTD .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 cell count great equal 300 cells/mm3 3 occasion prior protocol treatment . Plasma viral load Roche Amplicor HIV Monitor assay great equal 2,000 RNA copies/ml less equal 50,000 RNA copies/ml least 2 occasion prior protocol treatment . Normal nondiagnostic electrocardiogram . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Severe opportunistic infection medical condition opinion investigator contraindication enrol trial . Severe lactose intolerance . Concurrent Medication : Excluded : Concomitant therapy medication primary renal excretion ( 3TC , ddC , d4T ) . Prior Medication : Excluded : Ongoing dideoxyinosine antiretroviral therapy except ZDV , 3TC , ddC , d4T , saquinavir , ritonavir , indinavir , nelfinavir within 2 week study . Participation study systemic experimental drug within last 2 month . Required : Ongoing ( least 4 week ) stable dosage zidovudine ( ZDV ) lamivudine ( 3TC ) , ZDV stavudine ( d4T ) , ZDV zalcitabine ( ddC ) , d4T 3TC , ZDV alone , ddC alone , combination saquinavir , ritonavir , indinavir , nelfinavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1999</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>peldesine</keyword>
</DOC>